Managing Allergic Rhinitis: Effective Strategies (AAN)
Price: FREE for members and non-members
Session recorded on March 13, 2025
Speaker: Andrew A. White, MD, FACAAI
Allergic rhinitis, or hay fever, affects millions of people worldwide, leading to symptoms like sneezing, nasal congestion, itching, and watery eyes. While it may seem like just an inconvenience to some, for many, it can significantly impact quality of life—interfering with work, sleep, and daily activities. Dr. White will discuss the impact of allergic rhinitis on a patient's quality of life, share strategies for managing the condition, and provide information on emerging therapies
This program is a collaboration between the American College of Allergy, Asthma & Immunology and the Allergy and Asthma Network (AAN).
Explore other archived clinical webinars here.
Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
Primary Care Providers
Allied Health Professionals
Learning Objectives
Upon completion of this activity learners should be able to:
1. Analyze the impact of allergic rhinitis on quality of life, including its effects on work, sleep, and daily activities.
2. Evaluate evidence-based pharmacological and non-pharmacological strategies for managing allergic rhinitis, incorporating the latest treatment options.
3. Identify emerging therapies for allergic rhinitis, considering their potential role in improving patient outcomes.
All identified relevant financial relationships with ineligible companies have been mitigated.
Speaker:
Andrew A. White, MD, FACAAI
Speaker: Amgen, AstraZeneca, Blueprint Medicine, Genentech, GSK
Advisor: AstraZeneca, Blueprint Medicine, GSK
Moderator:
De De Gardner, DrPH, RRT, RRT-NPS, FAARC, FCCP
Chief Research Officer, AAN Staff
Research: Novartis, Sanofi
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance